Evidence map›Paper›PMID 40857665›Full record

ArticleBlood2025

Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.

Jacob A Myers, Rih-Sheng Huang, Shee Kwan Phung, Jeremy M Chacón, Laura Bendzick, Anna Weis, Mihir Shetty, Taylor A DePauw, Melissa J Khaw, Juan E Abrahante and 8 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jacob A MyersMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-4166-2356
Rih-Sheng HuangMasonic Cancer Center, University of Minnesota, Minneapolis, MN.
Shee Kwan PhungMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0001-9700-0151
Jeremy M ChacónResearch and Innovation Office, Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-6129-2604
Laura BendzickMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-3197-5885
Anna WeisMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0009-0003-9158-3634
Mihir ShettyMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-9812-0515
Taylor A DePauwDepartment of Laboratory Medicine and Pathology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN.ORCID 0009-0006-5235-753X
Melissa J KhawMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-4207-9151
Juan E AbrahanteResearch and Innovation Office, Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN.
Stephen D O'FlanaganDepartment of Laboratory Medicine and Pathology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN.ORCID 0000-0002-9286-1208
K Maude AshbyAllergy Division, Feinberg School of Medicine, Northwestern University, Chicago, IL.ORCID 0000-0002-6297-5941
John R LozadaMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0001-8953-4110
Stephen C JamesonDepartment of Laboratory Medicine and Pathology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN.ORCID 0000-0001-9137-1146
Justin H HwangMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-1686-7103
Frank CichockiMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-3043-0653
Martin FelicesMasonic Cancer Center, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-5945-0634
Jeffrey S MillerMasonic Cancer Center, University of Minnesota, Minneapolis, MN.

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumorsR35CA283892 · NCI · UNIVERSITY OF MINNESOTA · PI Jeffrey S. Miller · 2023 to 2026
$3.7M
Tissue-Resident Adaptive CD56bright NK Cell Responses in CancerF30CA294723 · NCI · UNIVERSITY OF MINNESOTA · PI John Roy Lozada · 2024 to 2026
$142k
NCI NIH HHS F30 CA294723NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS R35 CA283892NIGMS NIH HHS T32 GM008244
6 · The paper itself

Abstract

abstractAdoptive transfer of natural killer (NK) cells can induce complete remissions in 30% to 50% of patients with refractory acute myeloid leukemia and lymphoma. Although blood chimerism occurs, attaining functional homing to the site of tumor without exhaustion has been elusive. During chronic infections and tumorigenesis, exposure to activating stimuli weakens the effector activity of NK cells. Despite this knowledge, there is little known about the mechanisms that govern this dysregulation and whether these disparate activating stimuli use distinct pathways to downregulate effector immunity. In this study, we reveal that chronic NK cell activation receptor (NKAR) stimulation and chronic interleukin-15 exposure impart distinct modes of dysregulation, with NKAR stimulation inducing a tissue resident-like state that resembles that of tumor-infiltrating NK cells in patients with cancer. Using loss- and gain-of-function studies, we identify the transcription factor KLF2 as a master regulator of the NK cell response to chronic activation and provide evidence that KLF2 overexpression promotes NK cell cytotoxicity, cytokine production, and chemotaxis and inhibits the development of dysfunctional, tissue resident-like features. Using KLF2 reporter mice, we show that in certain tissues, tissue resident NK cells are predominantly KLF2-, whereas circulating NK cells in these tissues are overwhelmingly KLF2+. Lastly, using mixed bone marrow chimeras, we demonstrate that conditional KLF2 deficiency in NK cells leads to altered homing and the acquisition of tissue resident-like features in vivo. Together, these findings highlight the profound changes NK cells undergo during prolonged activation and advance our understanding of how some NK cell therapies fail during malignant relapse.

Indexed as

Killer Cells, NaturalKruppel-Like Transcription FactorsLymphocyte ActivationAnimalsHumansInterleukin-15MiceMice, Inbred C57BLMice, KnockoutInterleukin-15Klf2 protein, mouseKruppel-Like Transcription Factors

Identifiers

PMID40857665
PMCPMC12983028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.